Comparison

Nacubactam European Partner

Item no. HY-109008-100mg
Manufacturer MedChem Express
CASRN 1452458-86-4
Amount 100 mg
Quantity options 100 mg 10 mM/1 mL 10 mg 50 mg 5 mg
Category
Type Inhibitors
Specific against other
Purity 99.30
Citations [1]Morinaka A, et al. In Vitro and In Vivo Activities of OP0595, a New Diazabicyclooctane, against CTX-M-15-Positive Escherichia coli and KPC-Positive Klebsiella pneumoniae. Antimicrob Agents Chemother. 2016 Apr 22;60(5):3001-6.|[2]Monogue ML, et al. In Vivo Efficacy of Meropenem with a Novel Non-β-Lactam-β-Lactamase Inhibitor, Nacubactam, against Gram-Negative Organisms Exhibiting Various Resistance Mechanisms in a Murine Complicated Urinary Tract Infection Model. Antimicrob Agents Chemother. 2018 Aug 27;62(9):e02596-17.|[3]Misawa K, et al. In vitro effects of diazabicyclooctane β-lactamase inhibitors relebactam and nacubactam against three subspecies of Mycobacterium abscessus complex. Int J Antimicrob Agents. 2022 Nov-Dec;60(5-6):106669.|[4]Kaushik A, et al. New β-Lactamase Inhibitors Nacubactam and Zidebactam Improve the In Vitro Activity of β-Lactam Antibiotics against Mycobacterium abscessus Complex Clinical Isolates. Antimicrob Agents Chemother. 2019 Aug 23;63(9):e00733-19.|[5]Barnes MD, et al. Nacubactam Enhances Meropenem Activity against Carbapenem-Resistant Klebsiella pneumoniae Producing KPC. Antimicrob Agents Chemother. 2019 Jul 25;63(8):e00432-19. |[6]Livermore DM, et al. Activity of OP0595/β-lactam combinations against Gram-negative bacteria with extended-spectrum, AmpC and carbapenem-hydrolysing β-lactamases. J Antimicrob Chemother. 2015 Nov;70(11):3032-41.
Smiles O=S(ON1[C@]2([H])CC[C@@H](C(NOCCN)=O)[N@@](C2)C1=O)(O)=O
ECLASS 10.1 32160490
ECLASS 11.0 32160490
UNSPSC 12000000
Alias OP0595 (free acid)
Shipping Condition Cool pack
Available
Manufacturer - Type
Reference compound
Manufacturer - Applications
COVID-19-immunoregulation
Manufacturer - Targets
Bacterial; Beta-lactamase
Shipping Temperature
Blue Ice
Storage Conditions
-20°C (Powder, protect from light, stored under nitrogen)
Molecular Weight
324.31
Product Description
Nacubactam (OP0595 free acid) is a potent non-β-lactam-β-lactamase inhibitor with activity against class A and C β-lactamases. Nacubactam acts as a penicillin binding protein (PBP) 2-active antibacterial, and gives β-lactamase-independent potentiation of β-lactams targeting other PBPs. Nacubactam potentiates the antimicrobial activities of Piperacillin (HY-B1923), Cefepime (HY-B0692), and Meropenem (HY-13678) against CTX-M-15-positive Escherichia coli and KPC-positive Klebsiella pneumoniae[1][2][3][4][5][6].
Manufacturer - Research Area
Infection
Solubility
DMSO: 250 mg/mL (ultrasonic)|H2O: 50 mg/mL (ultrasonic; warming; heat to 60°C)
Manufacturer - Pathway
Anti-infection
Clinical information
Phase 3

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 100 mg
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close